Dr. Reddy’s Laboratories Ltd $RDY Stock Holdings Boosted by Wealthstream Advisors Inc.

Wealthstream Advisors Inc. lifted its position in shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) by 52.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 17,678 shares of the company’s stock after acquiring an additional 6,055 shares during the period. Wealthstream Advisors Inc.’s holdings in Dr. Reddy’s Laboratories were worth $266,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of RDY. BNP Paribas Financial Markets grew its position in shares of Dr. Reddy’s Laboratories by 58.0% during the first quarter. BNP Paribas Financial Markets now owns 4,583,333 shares of the company’s stock worth $60,454,000 after acquiring an additional 1,682,363 shares during the last quarter. Millennium Management LLC grew its position in shares of Dr. Reddy’s Laboratories by 53.1% during the first quarter. Millennium Management LLC now owns 4,344,000 shares of the company’s stock worth $57,297,000 after acquiring an additional 1,506,368 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Dr. Reddy’s Laboratories by 13.6% during the second quarter. Robeco Institutional Asset Management B.V. now owns 12,163,428 shares of the company’s stock worth $182,816,000 after acquiring an additional 1,452,192 shares during the last quarter. Jump Financial LLC grew its position in shares of Dr. Reddy’s Laboratories by 534.1% during the first quarter. Jump Financial LLC now owns 147,111 shares of the company’s stock worth $1,940,000 after acquiring an additional 123,911 shares during the last quarter. Finally, Allianz Asset Management GmbH grew its position in shares of Dr. Reddy’s Laboratories by 37.4% during the second quarter. Allianz Asset Management GmbH now owns 441,451 shares of the company’s stock worth $6,635,000 after acquiring an additional 120,180 shares during the last quarter. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Performance

RDY stock opened at $14.44 on Friday. The company has a market capitalization of $12.05 billion, a P/E ratio of 21.87, a PEG ratio of 5.69 and a beta of 0.40. The company has a 50-day simple moving average of $14.30 and a 200 day simple moving average of $14.32. Dr. Reddy’s Laboratories Ltd has a fifty-two week low of $12.26 and a fifty-two week high of $16.17. The company has a quick ratio of 1.36, a current ratio of 1.89 and a debt-to-equity ratio of 0.01.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. Dr. Reddy’s Laboratories had a net margin of 16.99% and a return on equity of 17.25%. The company had revenue of $988.82 million during the quarter, compared to the consensus estimate of $88.27 billion. Sell-side analysts predict that Dr. Reddy’s Laboratories Ltd will post 0.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on RDY. Zacks Research upgraded shares of Dr. Reddy’s Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Dr. Reddy’s Laboratories in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Moderate Buy” and an average price target of $16.95.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.